Head-To-Head Analysis: Monte Rosa Therapeutics (GLUE) versus Its Peers

Monte Rosa Therapeutics (NASDAQ:GLUE) is one of 844 publicly-traded companies in the “Biotechnology” industry, but how does it compare to its peers? We will compare Monte Rosa Therapeutics to similar businesses based on the strength of its valuation, profitability, analyst recommendations, dividends, earnings, risk and institutional ownership.

Valuation and Earnings

This table compares Monte Rosa Therapeutics and its peers gross revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Monte Rosa Therapeutics	$70.33 million	-$38.63 million	-6.65
Monte Rosa Therapeutics Competitors	$756.44 million	$13.58 million	-18.85

Monte Rosa Therapeutics’ peers have higher revenue and earnings than Monte Rosa Therapeutics. Monte Rosa Therapeutics is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.

Institutional & Insider Ownership

80.0% of Monte Rosa Therapeutics shares are held by institutional investors. Comparatively, 47.8% of shares of all “Biotechnology” companies are held by institutional investors. 6.4% of Monte Rosa Therapeutics shares are held by company insiders. Comparatively, 13.1% of shares of all “Biotechnology” companies are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Analyst Ratings

This is a summary of current ratings for Monte Rosa Therapeutics and its peers, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Monte Rosa Therapeutics	1	2	8	1	2.75
Monte Rosa Therapeutics Competitors	9869	15284	45613	1598	2.54

Monte Rosa Therapeutics presently has a consensus price target of $26.44, suggesting a potential upside of 184.04%. As a group, “Biotechnology” companies have a potential upside of 124.54%. Given Monte Rosa Therapeutics’ stronger consensus rating and higher possible upside, analysts clearly believe Monte Rosa Therapeutics is more favorable than its peers.

Risk and Volatility

Monte Rosa Therapeutics has a beta of 1.4, suggesting that its stock price is 40% more volatile than the S&P 500. Comparatively, Monte Rosa Therapeutics’ peers have a beta of -1.84, suggesting that their average stock price is 284% less volatile than the S&P 500.

Profitability

This table compares Monte Rosa Therapeutics and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Monte Rosa Therapeutics	-186.24%	-30.14%	-20.35%
Monte Rosa Therapeutics Competitors	-12,323.33%	-195.38%	-30.39%

Summary

Monte Rosa Therapeutics beats its peers on 10 of the 13 factors compared.

Monte Rosa Therapeutics Company Profile

Monte Rosa Therapeutics is a clinical-stage biotechnology company developing molecular glue degraders, medicines designed to direct disease-associated proteins for disposal by the cell. Its discovery platform combines computational and experimental methods to identify and develop these potential treatments. The company’s research has included programs for cancer and immune-mediated diseases. Its pipeline includes MRT-6160, a VAV1 degrader being developed for autoimmune and inflammatory conditions, and MRT-8102, an investigational degrader targeting the NLRP3 inflammasome pathway.